The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.05
Bid: 3.00
Ask: 3.10
Change: 0.00 (0.00%)
Spread: 0.10 (3.333%)
Open: 3.05
High: 3.15
Low: 3.05
Prev. Close: 3.05
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

Tue, 19th Mar 2024 19:47

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

TMT Investments PLC - venture capital investor in high-growth technology companies - Reports net asset value per share of USD6.62 in the year ending December 31, rising 3.3% from USD6.41 the year prior. Total NAV rose to USD208.1 million from USD201.7 million. Explains improvement was mainly as a result of the upward revaluation of Backblaze and Collectly during the period. "With no financial debt and cash and cash equivalent reserves of USD11.0 million," TMT is "well positioned to ride out the current market volatility and to continue making investments and realising full and partial disposals when the right opportunities present themselves."

----------

Ten Lifestyle Group PLC - London-based lifestyle and travel services company - Issues trading update for six months to February 29. Expects to report half year net revenue of around GBP30.9 million, unchanged from last year, or up 4% at constant currency. Says active members continue to grow, up 13% to 356,000 from 316,000 last year. Explains the group secured and launched some significant contracts during the period that are expected to generate revenue in the second half of the year. Adjusted earnings before interest, tax, depreciation and amortisation is expected to be around GBP5.3 million, up from GBP5.0 million last year. At the end of the first half, says cash and cash equivalents were GBP8.0 million, compared to GBP8.2 million at the previous year-end.

----------

First Class Metals PLC - Ontario, Canada-focused exploration company - Signs sixty day exclusivity agreement with Emerald Geological Services Ltd in respect of an earn-in to the McInnes Lake Property in Ontario. Chief Executive Marc Sale comments: "This is an exciting development for FCM greenfield exploration opportunities on a property which potentially contains the same structure that is present at Red Lake. The lack of previous systematic or comprehensive exploration in a favourable geological setting presents realistic expectation for a significant discovery." Pays CAD5,000, around GBP2,897, for the exclusivity period.

----------

ValiRx PLC - Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics - Starts search for a chief executive officer to lead the next stage of growth. Expects the process may take a number of months, during which period Suzy Dilly will remain as CEO. As part of the re-structuring process, Dilly and the board will consider potential alternative roles. In addition, Adrian de Courcey joins the board as non-executive director.

----------

Atlantic Lithium Ltd - lithium development company, currently focused on developing the Ewoyaa project on the Ghanaian coast - Announces further broad and high-grade assay results from resource drilling completed at the Ewoyaa lithium project in Ghana. Notes multiple high-grade and broad extensional drill intersections reported at the new Dog-Leg target. Describes results at Dog-Leg as "significant". Points out drilling has intersected shallow dipping, near surface mineralised pegmatite bodies with true thicknesses up to 35m outside of the mineral resource estimate, proving potential for significant resource growth. Plans to advance the drilling programme to be undertaken in 2024. A mineral resource estimate upgrade, for both lithium and feldspar, to incorporate all 2023 and 2024 drilling, is targeted for the second half of 2024.

----------

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Agrees to buy Chronos Therapeutics Ltd for initial GBP899,481, or 1.44 pence per share. Explains price could rise to GBP3.4 million subject to the achievement of certain milestones. Chronos features a neuropsychiatry portfolio including two assets developed to late pre-clinical stage. Further, raises GBP0.85 million via placing and subscription at 1p each. In addition, announces retail offer to raise up to GBP1 million. Proceeds of the fund raise will be used for working capital and to maintain the enlarged group's patent portfolio. Plans name change to TheraCryf PLC.

----------

Impellam Group PLC - Luton, England-based specialist recruitment solutions provider - Says High Court sanctions scheme by which bid from HeadFirst Global BV will be facilitated. Expects scheme to become effective on Thursday, when shares will also be suspended.

----------

Custodian Property Income Reit PLC - real estate investment trust - Shareholders back resolution allowing company to allot shares or grant rights to subscribe for or convert any security into shares in the company in connection with the recommended merger with abrdn Property Income Trust Ltd. Chair David MacLellan says: "The board is pleased with the outcome of the vote, which demonstrated a very strong support from the CREI shareholders and further derisks the execution of the recommended merger." Encourages API shareholders to vote in favour of the scheme.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
9 Jan 2019 14:57

ValiRx gives NHS Long Term Plan its seal of approval

(Sharecast News) - Clinical stage biotechnology company ValiRx endorsed the Government's new NHS Long Term Plan to improve the quality of patient care and health outcomes on Wednesday.

Read more
9 Jan 2019 11:25

ValiRx Backs New Long-Term UK Government Plan For NHS

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Wednesday said it endorses the UK government's new NHS long-term plan."The government's recently announced ten-year a

Read more
18 Dec 2018 15:53

VAL401 results accepted for journal publication, says ValiRx

(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acceptance for publication of the first article containing results from the VAL401 clinical trial by the European Journal of Drug Metabolism and Pharmacokinetics on Tuesday.

Read more
10 Dec 2018 11:07

ValiRx releases positive data from recent VAL201 testing

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Monday that independent analysis of VAL201 data showed a "statistically significant" dose dependant response in the reduction of PSA correlated to time on the Phase l/ll clinical trial, involving patients with hormone-sensitive and hormone-resistant prostate cancer.

Read more
10 Dec 2018 10:59

WINNERS & LOSERS SUMMARY: Just Group Jumps 23% On Regulatory Decision

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------NMC up The

Read more
10 Dec 2018 09:06

ValiRx Reports Positive VAL201 Effect On Patients With Prostate Cancer

LONDON (Alliance News) - ValiRx PLC on Monday said an independent analysis of VAL201 showed a positive effect on patients with hormone-sensitive and hormone-resistant prostate cancer.The up

Read more
17 Oct 2018 08:36

ValiRx enters finals stages of clinical trials on VAL201

(Sharecast News) - Clinical stage biotechnology company ValiRx's leading anti-cancer therapeutic has entered the concluding stages of its Phase l/ll clinical trial at University College London Hospital.

Read more
25 Sep 2018 13:23

ValiRx Half Year Loss Widens On Expenses And Share Option Charge

LONDON (Alliance News) - Life science company ValiRx PLC on Tuesday reported a widened loss in the first half of 2018 due to expenses and a sizeable share option charge.The company's to

Read more
6 Sep 2018 11:38

ValiRx Says Clinical Study For Lung Cancer Drug VAL401 Is Approved

LONDON (Alliance News) - Clinical stage biotechnology company ValiRx PLC said Thursday its clinical study report on lung cancer drug VAL401 has been signed and approved by principal in ValiRx were

Read more
6 Sep 2018 09:05

ValiRx enters 'very exciting' phase for cancer therapies

(Sharecast News) - ValiRx told investors on Thursday that its clinical-stage therapeutics had continued to demonstrate "significant potential" for addressing unmet medical needs in oncology.

Read more
14 Jun 2018 11:00

WINNERS & LOSERS SUMMARY: Rolls Royce Flies High With Planned Job Cuts

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.6%. The jet engine maker said it will cut

Read more
11 May 2018 16:43

Nicholas Slater Increases ValiRx Stake To 4.5% From 2.7% (ALLISS)

LONDON (Alliance News) - ValiRx PLC said Friday Nicholas Slater had almost doubled his stake in life science company, which focuses on cancer treatments, to 4.5% after a transaction on raised his

Read more
4 May 2018 17:08

ValiRx Raises GBP950,000 Through Placing To Progress Pipeline (ALLISS)

LONDON (Alliance News) - ValiRx PLC said Friday it has raised GBP950,000 through the issue of 47.5 million shares at 2.00 pence per share.The clinical stage biotechnology company's down

Read more
25 Apr 2018 13:41

"Major" Milestone As ValiRx's VAL201 Is Granted Patent In EU

LONDON (Alliance News) - Biotechnology company ValiRx PLC said Wednesday its VAL201 compound has been granted a patent in the EU.This, it said, follows a US patent which was granted for a a

Read more
19 Apr 2018 12:41

ValiRx Posts Positive Results From VAL101 Compound Pre-Clinical Trials

LONDON (Alliance News) - ValiRx PLC on Thursday said pre-clinical studies showed that its VAL101 compund has a potential to prevent cancer growth at cellular biochemical and genomic molecule is is

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.